Merck changes French set-up:
This article was originally published in Clinica
Merck KGaA has reorganised its activities in France into one company to be known as Merck Lipha. The reorganisation involves the merging of Merck Clevenot, which manufactures diagnostic reagents and lab equipment, with pharmaceutical manufacturer, Lipha. Jean-Noel Treilles, currently president of Lipha, will head the new company and Karl Heinz Peter, president of Merck Clevenot, will become vice-president.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.